This podcast is based on the EASL Studio episode hosted on the occasion of the Rare Liver Diseases Month.

This episode focused on rare liver diseases, in particular, Progressive Familial Intrahepatic Cholestasis (PFIC). Discussions covered:

• Clinical presentation of PFIC
• Current therapeutic options
• The introduction of IBAT/ASBT inhibitors and their impact
• Clinical trials
• Orphan drugs approved for PFIC
• Interview with EMA on the orphan drug programme

This EASL Studio episode was supported by Albireo Pharma and Mirum Pharmaceuticals.

Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2e1-new-treatment-options-hereditary-cholestasis-syndromes-game-changer